Mylan CEO Claims EpiPens Aren’t As Profitable As Everyone Thinks

(By Alison Kodjak for NPR)

The drug company that makes the EpiPen says it isn’t nearly as profitable as many people assume it is. Continue reading article here…..

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.